Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

Saved in:
Bibliographic Details
Title: Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Authors: Liu X; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Shaw RH; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Stuart ASV; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Greenland M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Aley PK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Andrews NJ; Statistics, Modelling and Economics Department, Public Health England, London, UK; Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, UK., Cameron JC; Health Protection Scotland, Glasgow, UK., Charlton S; Public Health England, Porton Down, Salisbury, UK., Clutterbuck EA; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Collins AM; Liverpool School of Tropical Medicine, Liverpool, UK., Dinesh T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., England A; Public Health England, Porton Down, Salisbury, UK., Faust SN; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Ferreira DM; Liverpool School of Tropical Medicine, Liverpool, UK., Finn A; School of Population Health Sciences and School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK., Green CA; NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Hallis B; Public Health England, Porton Down, Salisbury, UK., Heath PT; The Vaccine Institute, St George's University of London, London, UK., Hill H; Liverpool School of Tropical Medicine, Liverpool, UK., Lambe T; Jenner Institute, University of Oxford, Oxford, UK., Lazarus R; North Bristol NHS Trust, Bristol, UK., Libri V; NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK., Long F; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Mujadidi YF; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Plested EL; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Provstgaard-Morys S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Ramasamy MN; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Ramsay M; Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, UK., Read RC; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Robinson H; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Singh N; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Turner DPJ; University of Nottingham, Nottingham, UK; Nottingham University Hospitals NHS Trust, Nottingham, UK., Turner PJ; National Heart and Lung Institute, Imperial College London, London, UK., Walker LL; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., White R; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Nguyen-Van-Tam JS; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK., Snape MD; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: matthew.snape@paediatrics.ox.ac.uk.
Corporate Authors: Com-COV Study Group
Source: Lancet (London, England) [Lancet] 2021 Sep 04; Vol. 398 (10303), pp. 856-869. Date of Electronic Publication: 2021 Aug 06.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(21)01694-9